<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03623997</url>
  </required_header>
  <id_info>
    <org_study_id>FeSupp_Anemia</org_study_id>
    <nct_id>NCT03623997</nct_id>
  </id_info>
  <brief_title>Measuring Erythrocyte Iron Incorporation From Different Dosing Regimens in Anemic Women</brief_title>
  <official_title>Defining Systemic Control of Iron Absorption to Optimize Oral Iron Supplementation Regiemns for Women With Iron Deficiency Anemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Swiss Federal Institute of Technology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Swiss Federal Institute of Technology</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Iron-deficient anaemic subjects are likely to benefit most from oral iron supplements, but
      supplementation schedules vary widely in clinical practice, absorption is low and compliance
      is poor due to mild gastrointestinal side effects. The investigators will compare iron
      absorption from labeled oral iron doses of 100mg and 200mg administered either on two
      consecutive days or on alternate days in young anemic women.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 10, 2017</start_date>
  <completion_date type="Actual">June 30, 2018</completion_date>
  <primary_completion_date type="Actual">January 8, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Fractional and total iron absorption</measure>
    <time_frame>absorption will be measured 14days after the 100mg and 200mg cycle</time_frame>
    <description>Fractional and total iron absorption from different supplementation regimens</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum hepcidin</measure>
    <time_frame>right before the administration of an iron dose</time_frame>
    <description>Serum hepcidin after the administration of different doses and using different regimens</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum EPO</measure>
    <time_frame>right before the administration of an iron dose</time_frame>
    <description>Serum EPO after the administration of different doses and using different</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum ferritin</measure>
    <time_frame>right before the administration of an iron dose</time_frame>
    <description>Determination of iron status</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum TfR</measure>
    <time_frame>right before the administration of an iron dose</time_frame>
    <description>Determination of iron status</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum CRP</measure>
    <time_frame>right before the administration of an iron dose</time_frame>
    <description>Determination of inflammation status</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum AGP</measure>
    <time_frame>right before the administration of an iron dose</time_frame>
    <description>Determination of inflammation status</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum iron</measure>
    <time_frame>right before the administration of an iron dose</time_frame>
    <description>Determination of iron status</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total iron binding capacity</measure>
    <time_frame>right before the administration of an iron dose</time_frame>
    <description>Determination of iron status</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">20</enrollment>
  <condition>Iron Deficiency Anemia</condition>
  <arm_group>
    <arm_group_label>Stable isotope labeled iron II sulfate</arm_group_label>
    <description>All subjects will go through two iron absorption study cycles. In one cycle they get 100mg oral iron labeled with stable isotopes on two consecutive and on one alternate day and in another cycle they get 200mg oral iron labeled with stable isotopes on two consecutive and on one alternate day. Half of the subjects start with the 100mg cycle whereas the other half starts with the 200mg cycle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Iron stable isotope labeled iron(II) sulfate</intervention_name>
    <description>Administration of oral stable isotope labels using different dosings and different regimens in women with iron deficiency anemia</description>
    <arm_group_label>Stable isotope labeled iron II sulfate</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Young women with iron-deficiency anemia
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ferritin &lt;15 Âµg/L

          -  Hb 8-11.9 g/dl

          -  BMI 18.5-24.9 kg/m2

          -  Body weight &lt;70 kg

        Exclusion Criteria:

          -  Severe anemia (Hb &lt;8 g/dl)

          -  Elevated CRP &gt;5.0 mg/L

          -  Chronic disease

          -  Long-term medication, except contraception

          -  Consumption of Mineral and Vitamin supplements within the study period

          -  Therapeutic iron infusion over the past 6 months

          -  Pregnancy or breastfeeding

          -  Smoking
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Human Nutrition Laboratory ETH Zurich</name>
      <address>
        <city>Zurich</city>
        <zip>8092</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>November 6, 2017</study_first_submitted>
  <study_first_submitted_qc>August 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 9, 2018</study_first_posted>
  <last_update_submitted>August 20, 2018</last_update_submitted>
  <last_update_submitted_qc>August 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Swiss Federal Institute of Technology</investigator_affiliation>
    <investigator_full_name>Prof. Michael B. Zimmermann</investigator_full_name>
    <investigator_title>Prof. Dr. med</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Anemia, Iron-Deficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

